| Compound | SS-31 (Elamipretide) |
|---|---|
| Category | Cardiolipin-binding mitochondrial peptide |
| Class | Metabolic and Mitochondrial Compounds |
| Evidence tier | Clinical-stage |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
SS-31 (Elamipretide) is catalogued here as a cardiolipin-binding mitochondrial peptide and graded at the "Clinical-stage" evidence tier. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
A tetrapeptide that binds cardiolipin on the inner mitochondrial membrane, developed for mitochondrial and cardiac diseases. It has completed multiple phase trials without yet securing approval.
Mechanism of Action
Elamipretide stabilizes cardiolipin interactions within the electron-transport chain, proposed to restore efficient respiration under mitochondrial stress.
Research and Evidence
Phase 3 MMPOWER-3 in primary mitochondrial myopathy missed its primary endpoint, but programs continue — notably in Barth syndrome, where cardiac benefit signals emerged.
Safety and Side Effects
Trials report a generally tolerable profile, mostly injection-site reactions; full labeling awaits approval.
Frequently Asked Questions
What is the evidence tier of SS-31 (Elamipretide)?
SS-31 (Elamipretide) is graded "Clinical-stage" on this site. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
Is SS-31 (Elamipretide) an approved medicine?
No. Clinical-stage means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for SS-31 (Elamipretide)?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — registered elamipretide studies. [source]
Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.